Chessifying Regulated Science & Patent White Space
Pharma and energy R&D usually burns billions in sequential silos: medicinal chemists synthesize candidates for 18 months, only for patent litigators to discover fatal blocking claims right before clinical entry—forcing the lab to start over. ProfessorPatent plays both boards simultaneously, unifying Title 35 Patent Law and Multi-Fidelity 3D Physics to deliver biophysically validated molecules and ready-to-file patent applications in seconds instead of years.
Why Compressing 24 Months Into Seconds Is Worth $1B–$5B in NPV
Every month wasted in the sequential loop between medicinal chemists (“synthesize 500 peptides”) and patent attorneys (“Novo Nordisk's claim covers this—start over”) is a month of peak patent-protected monopoly revenue lost forever at the end of the 20-year statutory term.
Blockbuster GLP-1 and mRNA franchises generate $18B to $28B+ annually ($50M–$76.7M every 24 hours). Saving $15M in CRO and legal bills is secondary—even a 6-month acceleration in priority filing or commercial launch adds $1 Billion to $5 Billion in Net Present Value (NPV).
Thomson Reuters paid $650M for Casetext, BioNTech paid $680M for InstaDeep, and Roche paid $2.7B for Carmot's GLP-1s. Each ProfessorPatent vertical is auctioned as a 100% Intact Virgin Monopoly (8/8 Islands) via Path 1 Annual GCP VPC Lease ($75M/yr Min Reserve) or Path 2 Outright Acquisition ($1.5B Min Reserve = 20x ARR).
Three High-Stakes Frontiers Solved at Silicon Speed
Grounded in verbatim active patent claims from USPTO and EPO, paired with exact 3D biophysical and crystallographic coordinate oracles.
1. GLP-1 & Incretin Peptides
Navigates the dense patent thickets of Novo Nordisk and Eli Lilly. Employs Cryo-EM PDB: 6X18 orthosteric pocket masks, installs quaternary DPP-4 shields, and relocates albumin affinity anchors to achieve clean 100% FTO and once-monthly human PK.
2. Oncology mRNA Logic & LNPs
Circumvents BioNTech and Arbutus patents using covalently closed circular RNA (circRNA-CVB3 IRES) and microRNA Boolean tissue gates (miR-122 liver silencing). Pairs with quadruple-vitiated non-PEG plant sterol LNP matrices.
3. Solid-State Battery Lattices
Solves crystallographic space group symmetries to bypass Toyota and QuantumScape patents. Synthesizes Ge/P-free Chalcohalides and 0% H2S Anti-Perovskites, paired with a silver-free 0.4 μm Mg3N2-Li3N anode interlayer saving $19.50/kWh.
Landmark Counterfactual Case Studies
Real hard-science solutions discovered in silicon against the industry's most notorious patent thickets. Proof of non-infringement, biophysical superiority, and Title 35 immunity.
Clearing the $2B Arbutus Patent Thicket with a Quadruple-Vitiated LNP
Arbutus claims four-component lipid nanoparticles comprising 50.0–65.0 mol% cationic lipid, 4.0–10.0 mol% DSPC, 30.0–40.0 mol% cholesterol, and 0.5–2.0 mol% PEG-lipid. Both Moderna (SM-102) and Pfizer-BioNTech (ALC-0315) were trapped inside this corridor, triggering ongoing multi-billion dollar infringement litigation in Delaware.
All-Elements Vitiation: 0.0% Cholesterol (100% Phytosterol) | 0.0% PEG-Lipid (100% Polysarcosine) | 42.0% Cationic (< 50% box)
Under Warner-Jenkinson and the All-Elements Rule, literal infringement is defeated because the composition lacks both claimed cholesterol and PEG-lipid. Replacing cholesterol with β-sitosterol (having an ethyl branch at C24) and substituting PEG with polysarcosine operates through fundamentally distinct biophysical mechanisms, barring the Doctrine of Equivalents as a matter of law. Furthermore, Arbutus' prosecution narrowing amendments create absolute prosecution history estoppel.
// Multi-Fidelity Performance Delta Matrix
Verified via 3D Cryo-EM & Quantum DFT OraclesSealed-bid auction with a $75M/yr minimum reserve (<1 day of blockbuster GLP-1 revenue). Locks 100% of all 8/8 islands (zero leaks), takes this public vertical offline, and deploys air-gapped inside your private GCP/Firestore VPC.
20x multiple on $75M/yr ARR ($1.5B minimum reserve)—surpassing Casetext ($650M) & InstaDeep ($680M) while still a 45% discount to Roche's $2.7B Carmot GLP-1 buyout. Perpetual IP, code & 8/8 white-space spin-out.
To preserve 100% virgin monopoly value for Path 1 & Path 2 auction bidders, individual $25M single-cluster bids from venture biotechs are held in standby escrow—and only execute if neither the $75M/yr nor $1.5B reserve is met.
The 4 Wargaming Disciplines
Computes candidates in the strict mathematical complement of all active patent claims. Structural design-arounds defeat literal infringement and bar Doctrine of Equivalents via Warner-Jenkinson claim vitiation and Festo prosecution history estoppel.
Identifies super-performing species inside an incumbent's patent. Discovers when FDA de-risking, 35 U.S.C. § 271(e)(1) Clinical Trial Safe Harbor, and Two-Way Blocking Species Patents (In re Papesch) generate +$1.4B to +$3.8B higher rNPV than pure white space.
Pharma/battery R&D teams paste their proprietary internal lead molecule, LNP molar ratio, or solid electrolyte formula. The engine identifies exact CPC collisions in <5 ms and prescribes the minimal 1-step edit to achieve 100% clean clearance.
Generates 5 institutional deliverables in 1 click: formal 2-column FTO opinions, cGMP synthesis work orders, PTAB 37 CFR § 42.104 IPR petition briefs, native WIPO ST.26 / CIF structure files, and ready-to-file USPTO provisional drafts.
Ready to Explore the Live Interactive Discovery Arenas?
Input any clinical, formulation, or material objective in plain English and experience our Natural-Language-to-Physics Intent Compiler.